Genzyme gets backing for Mozobil in Wales, as UK's NICE takes political sabbatical

9 April 2010

US biotechnology firm Genzyme has welcomed the decision by the All Wales Medicines Strategy Group (AWMSG) to recommend its Mozobil (plerixafor) for use within the National Health Service in Wales.

Mozobil is a new stem-cell mobilization therapy aimed at improving results for patients who are undergoing stem cell transplantation as part of their treatment for multiple myeloma and lymphoma. Mozobil quickly mobilizes stem cells from the bone marrow into the blood stream for collection and offers hope for patients who might otherwise not be able to generate sufficient stem cells for a successful transplant. Mozobil has been shown to rapidly increase the number of stem cells available for collection in the blood stream.

This week's announcement by the AWMSG follows the Scottish Medicines Consortium's decision on use of Mozobil within NHS Scotland in January this year and positive recommendations by a number of individual health authorities in England.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK